Endpoint
Pancreatic cancer incidence
Tumors or cancer of the pancreas. Depending on the types of islet cells present in the tumors, various hormones can be secreted: glucagon from pancreatic alpha cells; insulin from pancreatic beta cells; and somatostatin from the somatostatin-secreting cells. Most are malignant except the insulin-producing tumors (insulinoma).
CAT:outcome/pancreatic-cancer-incidencereported in risk ratio2 findings from 2 compounds
What moved it
How to read these marks2 findings · 2 compounds · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| acrylamide | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| riboflavin | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
1 finding
riboflavin — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The risk of pancreatic cancer increased with increasing level of serum riboflavin in a dose-dependent manner, especially in men (Ptrend = 0.003).”
Quoted verbatim from The Association Between Serum Riboflavin and Flavin Mononucleotide With Pancreatic Cancer: Findings From a Prospective Cohort Study.. - Study
- case-control
- Population
- Nested case-control study within the Singapore Chinese Health Study (58 cases, 104 matched controls); exposure is endogenous serum riboflavin concentration across tertiles, not an administered dose
The Association Between Serum Riboflavin and Flavin Mononucleotide With Pancreatic Cancer: Findings From a Prospective Cohort Study.2023PMID:37523604Permalink
Measured, no effect detected
1 finding
acrylamide — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“We observed no association between dietary acrylamide intake and pancreatic cancer (Table 2).”
Quoted verbatim from Dietary Acrylamide Intake and the Risk of Pancreatic Cancer: The Japan Public Health Center-Based Prospective Study.. - Study
- cohort
- Population
- 89,729 Japanese men and women aged 45-74 years without prior cancer (JPHC Study), energy-adjusted dietary acrylamide intake by quartile, mean follow-up 15.2 years; whole-cohort result
Dietary Acrylamide Intake and the Risk of Pancreatic Cancer: The Japan Public Health Center-Based Prospective Study.2020PMID:33266487Permalink
How it is measured
Incident pancreatic cancer diagnoses ascertained by cancer registry linkage, pathology report, or medical record review.
Sources cited
2 papers
- Subject
- pancreatic cancer incidence
- Findings
- 2
- Papers
- 2
The Association Between Serum Riboflavin and Flavin Mononucleotide With Pancreatic Cancer: Findings From a Prospective Cohort Study.record2023PMID:375236041 finding
Dietary Acrylamide Intake and the Risk of Pancreatic Cancer: The Japan Public Health Center-Based Prospective Study.record2020PMID:332664871 finding